<DOC>
	<DOCNO>NCT01803087</DOCNO>
	<brief_summary>This clinical pharmacology want investigate systemic availability BDP/B17MP ( active metabolite BDP ) formoterol single oral inhalation CHF 1535 100/6 pMDI without spacer device ( AeroChamber Plus™ ) comparison free combination BDP pMDI plus formoterol pMDI license product ; additionally compare systemic exposure adult without spacer device .</brief_summary>
	<brief_title>Single-Dose Clinical Pharmacology Study Asthmatic Adolescent Adult Patients</brief_title>
	<detailed_description>The propose clinical pharmacology study aim investigate systemic availability BDP/B17MP ( active metabolite BDP ) formoterol single oral inhalation CHF 1535 100/6 pMDI ( reach total dose BDP 400 µg formoterol 24 µg ) without spacer device ( AeroChamber Plus™ ) comparison free combination BDP pMDI plus formoterol pMDI license product ( reach total dose BDP formoterol ) adolescent asthmatic patient . The systemic exposure BDP/B17MP formoterol inhalation CHF 1535 pMDI adolescent additionally compare systemic exposure adult without spacer device . The chosen dose correspond maximum daily dose two component administer fixed combination .</detailed_description>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Inclusion criterion Patients enrol meet follow criterion : 1 . Male female adolescent , age ≥ 12 &lt; 18 year time Screening Visit male female adult , age ≥ 18 ≤ 65 year time Screening Visit . 2 . Written inform consent obtain patient case adult patient parents/legal representative minor ( accord local regulation ) . 3 . A diagnosis asthma define GINA guideline ( updated 2010 ) 6 month screen visit . 4 . Male/female adolescent adult patient asthma stable enough , accord GINA guideline ( updated 2010 ) base Investigator 's opinion , allow wash period inhale BDP 2 day single day study treatment ICS BDP 1 day single day study treatment . 5 . Male/female adolescent adult asthmatic patient already treat ICS ICS/longacting inhale β2agonists use shortacting inhaled β2agonists reliever control asthma symptom . 6 . Adolescents adult force expiratory volume one second ( FEV1 ) &gt; 70 % predict value ( % pred ) withhold short act β2agonist treatment minimum 6 h prior screen 24 hour case long act β2agonist . 7 . Non exsmokers smoke less 5 packyears ( e.g . &lt; 20 cigarette per day 5 year ) stop smoke least 1 year . 8 . A cooperative attitude ability train proper use pMDI without spacer device compliant study procedure . 9 . Body mass index ( BMI ) ≥18.5 ≤ 32 kg/m2 Exclusion criterion Patients enrol one follow criterion present : 1 . Pregnant breastfeed female patient . Sexually active female use efficient contraception throughout entire study period ( e.g . oestroprogestatives , condom , intrauterine device ) . A urinary pregnancy test perform screen treatment visit ( mandatory adult population discretion investigator adolescent population ) woman childbearing potential ; 2 . Having receive investigational drug within 2 month screen visit ( Visit 1 ) . 3 . Diagnosis COPD , adult patient , define current GOLD guideline ( updated 2010 ) . 4 . Known hypersensitivity active treatment . 5 . Inability perform require breathing technique blood sample . 6 . Hospitalization due exacerbation asthma within 1 month prior screen visit . 7 . Lower respiratory tract infection within 1 month prior screen visit . 8 . Obesity , i.e . &gt; 97 % weight percentile local standard . 9 . Significant medical history and/or treatment cardiac , renal , neurological , hepatic , endocrine disease , may interfere patient 's safety , compliance , study evaluation , accord Investigator 's opinion ; 10 . History drug addiction excessive use alcohol ( weekly intake excess 28 unit alcohol ; one unit glass beer , wine measure spirit ) , excessive consumption xanthine contain substance ( daily intake excess 5 cup coffee , tea , cola , etc ) psychological emotional problem likely invalidate inform consent , limit ability subject comply protocol requirement ; 11 . Treatment xanthine derivative ( e.g . theophylline ) formulation 4 week prior screen ; 12 . Blood donation ( 450 mL ) ( adult population ) significant blood loss 12 week screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>adolescent</keyword>
	<keyword>adult</keyword>
</DOC>